- Home
- CRVO vs INKT Comparison
CRVO vs INKT Comparison
Compare CRVO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | INKT |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 70.6M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRVO | INKT |
|---|---|---|
| Price | $3.70 | $11.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $23.00 | ★ $35.00 |
| AVG Volume (30 Days) | 31.8K | ★ 47.5K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,006,510.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $6.66 |
| 52 Week High | $13.13 | $76.00 |
Technical Indicators
Market Signals| Indicator | CRVO | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 51.96 |
| Support Level | $3.55 | $10.94 |
| Resistance Level | $4.33 | $12.58 |
| Average True Range (ATR) | 0.25 | 1.09 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 2.67 | 29.10 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.